These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30504313)

  • 1. Where does PD-1 blockade fit in HL therapy?
    Herrera AF
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab in the Treatment of Hodgkin Lymphoma.
    Ansell SM
    Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
    Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
    Armand P; Shipp MA; Ribrag V; Michot JM; Zinzani PL; Kuruvilla J; Snyder ES; Ricart AD; Balakumaran A; Rose S; Moskowitz CH
    J Clin Oncol; 2016 Nov; 34(31):3733-3739. PubMed ID: 27354476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
    Dada R
    Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
    Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
    Bartlett NL
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
    Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
    Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
    Hradska K; Kascak M; Hajek R; Jelinek T
    Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
    [No Abstract]   [Full Text] [Related]  

  • 16. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
    Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
    J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab in classical Hodgkin's lymphoma.
    Maly J; Alinari L
    Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New molecular targets in Hodgkin and Reed-Sternberg cells.
    Sadaf H; Ambroziak M; Binkowski R; Kluebsoongnoen J; Paszkiewicz-Kozik E; Steciuk J; Markowicz S; Walewski J; Sarnowska E; Sarnowski TJ; Konopinski R
    Front Immunol; 2023; 14():1155468. PubMed ID: 37266436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.